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ABSTRACT
The ability to specifically engineer the genome of
living cells at precise locations using rare-cutting
designer endonucleases has broad implications for
biotechnology and medicine, particularly for func-
tional genomics, transgenics and gene therapy.
However, the potential impact of chromosomal
context and epigenetics on designer endonuclease-
mediated genome editing is poorly understood. To
address this question, we conducted a comprehen-
sive analysis on the efficacy of 37 endonucleases
derived from the quintessential I-CreI meganuclease
that were specifically designed to cleave 39 different
genomic targets. The analysis revealed that the
efficiency of targeted mutagenesis at a given
chromosomal locus is predictive of that of homolo-
gous gene targeting. Consequently, a strong
genome-wide correlation was apparent between
the efficiency of targeted mutagenesis (0.1% to
6%) with that of homologous gene targeting
(0.1% to 15%). In contrast, the efficiency of
targeted mutagenesis or homologous gene target-
ing at a given chromosomal locus does not correl-
ate with the activity of individual endonucleases
on transiently transfected substrates. Finally, we
demonstrate that chromatin accessibility modu-
lates the efficacy of rare-cutting endonucleases,
accounting for strong position effects. Thus,
chromosomal context and epigenetic mechanisms
may play a major role in the efficiency rare-cutting
endonuclease-induced genome engineering.
INTRODUCTION
The development of a comprehensive technology platform
to efﬁciently engineer the genome at speciﬁc sites in living
cells opens new opportunity for functional genomics,
generation of transgenic models, gene therapy, stem cell
engineering and regenerative medicine. Such targeted
genome modiﬁcation has typically been achieved using
different types of designer rare-cutting endonucleases
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that induce a DNA double-strand break (DSB) at a
desired speciﬁc location in the genome. Different scaffolds
have been used to generate these endonucleases (1,2), and
at least four families of such endonucleases have been
documented so far: zinc ﬁnger nucleases (ZFNs) (3–5),
meganucleases (MNs) from the LAGLIDADG family
(6,7), chemical nucleases (8,9) and transcription
activator-like nucleases (TALENs) (10–12). From a struc-
tural or chemical perspective, these designer rare-cutting
endonucleases differ in several respects, which have been
reviewed elsewhere (1,2). Consequently, one can expect
that each of these platforms will have different properties
in terms of efﬁcacy, speciﬁcity, range of cleavable se-
quences, spectrum of induced events (homologous gene
targeting versus targeted mutagenesis, see below), and
therefore, of potential applications.
MNs and ZFNs are currently the most well documented
and widely used reagents. The I-SceI MN has been used
since the 1990s in genome engineering experiments (13,14).
Redesign of the DNA binding interface of the I-CreI
MN by protein engineering has substantially increased
the number of sequences that can be cleaved (15,16).
Similarly, a large number of ZFNs with tailored
speciﬁcities have been generated and used by several
laboratories in a wide range of cell types (3–5,17–21).
Both MNs and ZFNs have the ability to deliver targeted
DSBs that subsequently undergo either non-homologous
end-joining (NHEJ) or homologous recombination
(HR) (1). NHEJ, an error prone DSB repair pathway,
has been used to inactivate the open reading frames of
selected genes by targeted mutagenesis (TM) (22,23). In
contrast, HR is used mainly for targeted gene insertion or
correction, by homologous gene targeting (HGT).
Although cleavage of promiscuous or ‘off-target’
sequences have also been observed, MNs and ZFNs
have both been used to induce precise gene modiﬁcations
without affecting global genome integrity, even in
organisms with large genomes such as ﬁsh, mammals
and plants (1).
Though genome editing based on these designer
rare-cutting endonucleases is determined by the recogni-
tion of a speciﬁc nucleotide target sequence, it is likely
that chromosomal context and epigenetic modiﬁcations
of target loci could also play an important role.
Consequently, chromatin accessibility and/or the position-
ing of nucleosomes in vivo (24,25) at the target locus may
impact TM and/or HGT. Alternatively, the location of
different target loci in distinct ‘chromosomal territories’
could possibly inﬂuence genome editing by modulating
access to limiting factors required for DNA repair (26).
To address these outstanding questions and assess the
potential impact of chromosomal position effects and
epigenetics on designer rare-cutting endonucleases, we
have conducted a comprehensive analysis of the properties
of MNs in human cells. We therefore monitored TM
and HGT efﬁcacies in an unprecedented large number of
chromosomal loci across the human genome and
determined the effect of chromatin accessibility on
genome editing by MNs. The current study contributes
to a better understanding of the properties of designer
rare-cutter endonucleases which has important fundamen-
tal biological and translational implications.
MATERIALS AND METHODS
Meganucleases
MNs derived from I-CreI were engineered as described
previously (16,27,28). All MNs were used under a single
chain format, as described in Grizot et al. (16), except for
CAPNS1m and NACAm which were used in 293-H cells
under a previously described heterodimeric format
(16,28).
293-H cells culture and transfections
Human 293-H cells (Life Technologies, Carlsbad, CA,
USA) and hamster CHO-KI cells (ATCC) were cultured
at 37C with 5% CO2 in complete medium DMEM and
F12-K, respectively, supplemented with 2mM L-glutam-
ine, penicillin (100 IU/ml), streptomycin (100mg/ml),
amphotericin B (Fongizone: 0.25mg/ml, Life Techno-
logies,) and 10% FBS. For extrachromosomal and
survival assays, CHO-KI cells were plated at 2500 cells
per well in 96-well plate. The next day, cells were trans-
fected with 200 ng of total DNA using Polyfect transfec-
tion reagent according to the supplier’s (Qiagen) protocol.
In the survival assay, a constant amount of GFP-encoding
plasmid (10 ng) was added to various amounts of MN
expression vectors. For mutagenesis and gene targeting
assays, 293-H cells were plated at a density of 1.2 106
cells per 10 cm dish. The next day, cells were transfected
with 3 or 5 mg of plasmid DNA using Lipofectamine 2000
transfection reagent (Life Technologies) according to the
manufacturer’s protocol.
Extrachromosomal activity assays in CHO-KI and
HEK293 cells
Activity in mammalian cells was measured as previously
reported by Grizot et al. (29) These assays are used to
monitor the activity of the MNs in a non-chromatinized
template, an activity that is a function of MN expression
and speciﬁc activity.
Cell survival assay
The CHO-KI cell line was transfected as described above,
with varying amounts of MN expression vector and a
constant amount of GFP-encoding plasmid. GFP levels
were monitored by ﬂow cytometry (Guava EasyCyte,
Guava Technologies) on Days 1 and 6 post-transfection.
Cell survival was calculated as a ratio (MN-transfected
cells expressing GFP on Day 6/control transfected cells
expressing GFP on Day 6) corrected for the transfection
efﬁciency determined on Day 1.
Area under the curve scores
Area under the curve (AUC) score is used to quantify
(i) the activity of MN in extrachromosomal assays
in CHO-KI and 293-H cells; (ii) cell survival in the
toxicity assay; (iii) chromatin resistance to microccocal
nuclease digestion at a given locus. Examples are given
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in Figure 2b and Supplementary Figure S2c. The classical
approach based on the use of log-normal model (30)
showed a very good ﬁtting quality for both survival
curves and activity curves (after normalization with
respect to the maximal activity level). All the statistics
done in this study are summarized in Supplementary
Table S6.
Western blot
293-H and CHO-KI cells were plated at 1.2 106 and
2 105 cells per 10 cm dish, respectively. These two cell
lines were transfected with the same DNA plasmid-
encoding MN: 3 mg for 293-H cells and 1 mg for
CHO-K1 cells, according to the usual transfection condi-
tion. Two days post-transfection, total protein extraction
was performed with RIPA (150mM sodium chloride, 1%
NP-40, 0.5% sodium deoxycholate, 01% SDS, 50mM
Tris pH 8.0) buffer. Western blot was performed on
10 mg of total protein extract. The MN expression was
revealed using a speciﬁc I-CreI antibody. Beta-tubulin
antibody (Cell signaling 2128) was used as loading
control. Quantiﬁcation of signal was performed on low
exposed blots using ImageJ software. Results were ex-
pressed as a ratio between MN and tubulin signals.
Monitoring of MN-induced TM
293-H cells were transfected with 3 mg of MN expressing
vector or empty vector, except for ADCY9-induced mu-
tagenesis where 293-H cells were transfected with 5 mg
of MN-encoding plasmid. Two days post-transfection,
genomic DNA was extracted and targets studied were
ampliﬁed with speciﬁc primers ﬂanked by speciﬁc
adaptators needed for HTS sequencing (For: CCATCTC
ATCCCTGCGTGTCTCCGACTCAG-Tag and Rev:
BiotinTEG/ CCTATCCCCTGTGTGCCTTGGCAGTC
TCAG) on the 454 sequencing system (454 Life
Sciences). An average of 10 000 sequences per sample
were analysed. Sequence of the primers used to amp-
lify the targeted locus are indicated on Supplementary
Table S3. In clonal experiments (Rag1m and
DMD21m), cells were plated after treatment and indi-
vidual clones were grown. After 21 days, DNA extraction
was performed with the ZR-96 genomic DNA kit (Zymo
research) according to the supplier’s protocol. The region
of the target was ampliﬁed by PCR as described above,
and PCR product was sequenced.
Monitoring of MN-induced HGT
293-H cells were co-transfected with 3 mg of MN express-
ing vector, and 2mg of DNA matrix and seeded at 10 cells
per well in 96-well plate, and HGT was monitored by PCR
21 days later. Alternatively, cells were plated and individ-
ual colonies were picked 2–3 weeks later in 96-well plates
and analysed (Supplementary Table S1). All DNA
matrices comprise 1 kb of homologous sequences located
on both sides of the MN recognition site. The two
homology arms are separated by a heterologous
fragment of 29 bp or 1.7 kb. DNA extraction was per-
formed with the ZR-96 genomic DNA kit (Zymo
research) according to the supplier’s protocol. The
detection of targeted integration is performed by speciﬁc
PCR ampliﬁcation using a primer located within the heter-
ologous insert of the DNA repair matrix, and another one
located on the genomic sequence outside of the homology.
In pool experiments (10 cells/well), HGT frequencies were
normalized to plating efﬁciencies, e.g. 0.33. This method
was validated by the good correlation between the
frequencies in clonal analysis and the frequencies in
pool analysis (Supplementary Table S1). Sequence of the
primers used to amplify the homologous regions is
available upon request. Sequence of the primers used
to diagnostic targeted integrations are indicated on
Supplementary Table S3. HGT was also conﬁrmed by
Southern Blot for Rag1m, DMD21m, ADCY9m,
XPC4m and CLS3690m.
Simultaneous monitoring of MN-induced HGT and TM
HEK293-H cells were co-transfected with plasmids ex-
pressing the MN and 2 mg of repair matrix. In each experi-
ment, we ampliﬁed the region surrounding the target site
by nested PCR using deep sequencing primers, with the
ﬁrst set of primers being located outside of the repair
matrix (see Supplementary Table S3 for primer
sequence). We measured both HGT and TM by deep
sequencing of the amplicons.
CHART-PCR
Cells were resuspended in 1ml of sucrose buffer supple-
mented with 0.5% of NP-40. The pellet nuclei was resus-
pended in ice-cold nuclei buffer supplemented with DTT
and PMSF at a concentration of 2 104 nuclei/ml.
Digestion was performed on 1.5 105 nuclei at room tem-
perature for 15min with 10–500 U of micrococcal nuclease
(Biolabs). Restriction cleavage was stopped by the
addition of 10mM EDTA. DNA was extracted in the
presence of proteinase K and then quantify with picogreen
(Quant-iTTM PicoGreen dsDNA Assay, Molecular
Probes). Q-PCR was performed in duplicate with speciﬁc
primers described in Supplementary Table S3. The data
are expressed as percentage of Q-PCR signal of undigested
sample.
RESULTS
Target selection
We have previously described a combinatorial method
to generate MNs that cleave selected sequences in virtually
any gene or locus (16,28,31). Brieﬂy, this approach
relies on the use of an archive of locally engineered deriva-
tives of the I-CreI MN. These MNs recognize targets
differing from the I-CreI target by a few base pairs only,
but can be used as building blocks to generate combina-
torial libraries of fully redesigned MNs. MNs recognizing
speciﬁc chosen targets, unrelated to the sequence
recognized by the parental I-CreI scaffold, are identiﬁed
using a high-throughput yeast cell assay. Typically, a
MN cleavage site is placed between two direct repeats
in a b-galactosidase (LacZ) reporter plasmid, as
extra-chromosomal target (Supplementary Figure S1).
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Cleavage of the target site by the MN in this cell-based
assay induces tandem-repeat recombination, by single-
strand annealing (SSA) between two truncated copies of
the LacZ gene thereby restoring a functional LacZ gene.
This method allowed for the identiﬁcation of a potential
cleavable target every 250 bp, with a success rate of 40%
at the protein engineering step (32). Based on this prin-
ciple, we generated a large collection of 37 different engin-
eered MNs, derived from the parental I-CreI natural
protein, that cleaved 39 different sequences, speciﬁcally
designed for genome editing in coding and non-coding
sequences of the human genome (Figure 1 and Table 1).
In this study, m refers to the MN and t its respective target
sequence. For instance, Rag1 designates the chosen locus,
Rag1m the MN, and Rag1t, the 22 bp target sequences
cleaved by the Rag1 MN. Our selection was prioritized
towards coding sequences, given their high potential
interest (i.e. gene inactivation and gene correction) and
translational relevance (i.e. gene therapy). Consequently,
this prioritization resulted in a higher proportion of
targets in GC- and CpG-rich regions (Figure 1b).
Characterization of MNs activity based on
extrachromosomal cellular assays
A quantitative cell-based assay in CHO-KI and 293-H
cells was used to characterize the MN activity of this
MN collection was used (Figure 2a and Table 1). This
extrachromosomal assay (29,31) is similar to the cellular
assay in yeast and allows for a quantitative assessment of
Figure 1. Genome-wide distribution of the targets of the MNs used in this study. (a) Schematic representation of the distribution per chromosome.
Thirty-seven MNs cleaving 39 targets were used in this study, including 36 MNs cleaving each single target (represented by ﬁlled-in triangles) and 1
MN (CLS3902m), cleaving 3 (represented by open triangles). Target sequences and MN properties are described in Table 1. (b) Distribution per type
of genomic sequence, per GC content and per CpG number. Distributions for target locations (top row) are compared with the distribution found
for the whole genome (bottom row, on assembly GRCh37/hg19). For the type of genomic sequences, two MN target sites are overlapping with an
intron/exon boundary and a special class was made for them. For GC content and CpG number, windows of 1 kb are taken around the recognition
site (top row) or successively on the whole genome (bottom row) and the percentage of GC or the number of CpG dinucleotides are computed.
Percentages in each class are displayed. The estimation of the percentage of sequences in exon, intron and intergenic regions on the whole genome is
based on available annotations. The human genome version we used was GRCh37/hg19.
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MN activity based on LacZ reporter gene expression
(Figure 2b). Importantly, the activity measured in this
extrachromosomal in vivo cellular assay depends not
only on the intrinsic speciﬁc activity of the MN, but also
on the MN expression level in the target cell. Whereas
speciﬁc activity can vary widely even between closely
related I-CreI derivatives (28,33), MN expression levels
can also be strongly affected by the few amino acid sub-
stitutions that differ from one engineered MN to another
(Figure 2c). Nevertheless, there is a strong correlation in
relative MN expression levels in different cell types, at
least based on 293-H and CHO-KI cells (Figure 2d).
Most importantly, when comparing MN activity in
CHO-KI and 293-H cells, we observed very consistent
results (Figure 2e), with linear (Pearson’s r) and non-linear
(Spearman’s r) correlation coefﬁcients ranging between
0.71 and 0.75, and P 0.002. We also compared MN
activity measured in our CHO-KI cell assay with that
obtained with aforementioned yeast assay, that also
measures MN-induced tandem repeat recombination on
a plasmid-borne reporter system (10,16,21,27). Here
again, we observed a very good consistency (r=0.8; and
r=0.79 with P< 2.2 1016 in both cases;
Supplementary Figure S1b), suggesting that our extra-
chromosomal assay in CHO cells is predictive for a wide
range of different cell types. This MN activity assay in
CHO cells therefore serves as an appropriate and repre-
sentative assay for MN activity.
MN-induced TM and HGT efﬁciencies are strongly
correlated
MNs were then tested for their efﬁcacy, deﬁned in this
study as their ability to induce targeted gene modiﬁcation
at their cognate chromosomal locus in human cells. Results
are summarized in Table 1. TMwas monitored for all MNs
by pyrosequencing of the targeted locus 7 days after trans-
fection of 3 mg of MN-expressing vector (Figure 3a). The
locus was ampliﬁed by PCR, and an average of 10 000 mol-
ecules was sequenced per amplicon. The MN-induced rate
varied between background level (up to 0.06% due to PCR
and sequencing errors) and 2.4% of the analyzed chroma-
tids (Table 1). HGT was monitored for 18 MNs by PCR in
pools of 10 cells grown in 96-well plates, 21 days after
transfection, as described previously (16) (Figure 3b).
HGT was also monitored in clonal experiments for
4 MNs, with the results conﬁrming the results from pools
in all cases (Supplementary Table S1). For the 18MNs that
were characterized for both TM and HGT, a strong linear
correlation (r=0.93 with P=2 108) was observed
between the frequency of TM ‘per chromatid’ and the fre-
quency of HGT ‘per cell’ throughout the target genome
(Figure 3c). Most importantly, this comprehensive
analysis revealed that the efﬁciency of TM at a given
chromosomal locus is predictive of that of HGT and that
the HGT/TM ratio is relatively conserved throughout the
genome.
In Figure 3c, we compared HGT events per cell and TM
events ‘per chromatid’ in 293-H cells. However, these
immortalized cells typically do not have a normal
diploid genome. Therefore, we reﬁned our analysis andT
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conducted additional studies to simultaneous monitor
HGT and TM ‘per chromatid’ by deep sequencing.
Events were monitored at Day 2, to alleviate toxicity
effect over time. Sixteen measurements were made with
seven different MNs (Supplementary Table S2). Again, a
very strong linear correlation (r=0.90 with
P=3 106) was observed between the frequency of
HGT ‘per chromatid’ and frequency of TM ‘per chroma-
tid’ (Figure 3d, Supplementary Table S2), and in this case,
a global HGT/TM ratio of 1.7 could be inferred from the
slope of the regression line.
MN efﬁcacies are poorly correlated with their activities
based on extrachromosomal substrates
The differences in MN efﬁcacy on chromosomal target loci
may reﬂect different parameters, particularly the activity
of a given MN, as measured using extrachromosomal
(a) (b)
(c)
(e)
(d)
I
Transfection
CHO-KI or 293-H cells
ONPG test (day 2)
Activity (AUC)
CLS4076m
Rag1m
I-SceI
MN 
Amount of transfected DNA (ng)
β-g
al
a
ct
os
id
as
e 
ac
tiv
ity
 (A
U) 4
3
2
1
0
4
3
2
1
0
0 2 4 6
0 2 84 6
AUC
SS
A 
in
 2
93
-H
 c
el
ls 
(A
UC
)
4       6      8     10     12    14
N=16
r=0.75; p=9x10-4
rho=0.71; p=2x10-3
1.0
1.5
2.0
2.5
3.0
3.5
0.5
SSA in CHO cells  (AUC)
CL
S4
07
6m
CA
PN
S1
m
AD
CY
9m
XP
C4
m
D
M
D
21
m
CL
S3
89
7m
R
ag
1m
W
AS
m
CL
S3
89
9m
Tubulin
MN293H
CHO
Relative expression in CHOR
el
a
tiv
e 
ex
pr
es
sio
n 
in
 2
93
-H
 
N=9
r=0.74; p=2.3X10-2
rho=0.80; p=1.4X10-2
Figure 2. Characterization of MNs properties using cell-based assays. (a) An extrachromosomal assay for the characterization of MN activity in
mammalian cells. Brieﬂy, MN expressing vectors and reporter vector are co-transfected into CHO-KI or 293-H cells. Upon cleavage of the target
site, tandem repeat recombination by SSA between two truncated copies of the LacZ gene restores a functional b-galactosidase gene, which can be
monitored by standard assays. For each MN, a dose response is performed and AUC is used as a quantitative measure of MN activity. (b) Example
of read out of the extrachromosomal assay described in panel. The activity of the CLS4076m, I-SceIm and Rag1m MNs is featured as an example.
AUC is used as a quantitative measure of MN activity in this type of extrachromosomal assay. For CLS4076, AUC is the area in grey. (c)
Monitoring of MN expression by western blotting. 293-H cells and CHO-K1 were transfected with a plasmid-encoding MN. The MN expression
level was monitored by western blot. (d) Quantiﬁcation of MN expression level. The MN expression level from western blot (c) was quantiﬁed and
normalized to b-tubulin signal. These ratios were plotted for both cell lines and statistical analysis was performed. r, Pearson coefﬁcient (linear
correlation coefﬁcient); r, Spearman coefﬁcient (non-linear correlation coefﬁcient); N, sample size; P, probability of ﬁnding a given correlation when
the underlying variables are not correlated. (e) Comparison between the extra-chromosomal SSA assays in CHO-KI and HEK293 cells. Sixteen MNs
were tested in both assays (Table 1). Dotted grey curves represent 95% conﬁdence interval for the regression line. r, Pearson coefﬁcient (linear
correlation coefﬁcient); r, Spearman coefﬁcient (non-linear correlation coefﬁcient); N, sample size; P, probability of ﬁnding a given correlation when
the underlying variables are not correlated.
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substrates, and/or MN-associated cellular toxicities.
However, other parameters may also contribute to these
differences in MN efﬁcacy, such as bona ﬁde target site-
dependent chromosomal position effects. Consequently,
MN efﬁcacy (i.e. TM, HGT) may result from a com-
bination of ‘intrinsic’ factors (i.e. MN activity, MN
toxicity) and ‘extrinsic’ factors (i.e. MN target locus).
To assess the contribution of each of these distinct
parameters on the overall MN efﬁcacy, we performed a
comprehensive quantitative analysis. We ﬁrst compared
MN efﬁcacy based on TM and HGT assays and MN
activity based on the extra-chromosomal assay, as
measured in CHO-KI and 293-H cells (Figure 4a).
Overall, MN efﬁcacies based on the frequency of TM
per chromatid correlated poorly with their respective in-
trinsic activities on extrachromosomal substrates (Figure
4a and b), consistent with the low correlation coefﬁcients
and P-values. A somewhat higher correlation was
observed only when comparing MN efﬁcacies (based on
the frequency of TM per chromatid) with activity in
CHO-KI cells (r=0.40 with P=102, r=0.41 with
P=8 103), and was statistically signiﬁcant only when
a large sample (n=39) was characterized (compare with
n=18 on Figure 4a), though the correlation coefﬁcient
remained low (r=0.40). Notably, some of the highest
frequencies of indels (as a measure of the frequency of
TM per chromatid) were achieved with DMD21m,
which has relatively moderate activities in the extrachro-
mosomal assay (Figure 4a and Table 1). Similarly, HGT
frequencies were poorly correlated with MN activity in
CHO-KI and 293-H cells (Figure 4c and d). These
modest correlations contrast with the high consistency
observed between the extrachromosomal tests (Figure 2e
and Supplementary Figure S1b) and between the two
types of efﬁcacy tests (Figure 3c and d).
Hence, the intrinsic activity of a given MN on extra-
chromosomal substrates is not predictive for its efﬁcacy on
chromosomal targets. Therefore, we decided to test the
impact of other factors.
MN efﬁcacies are not correlated with their
cellular toxicity
It has been shown before that in a population of cells
treated with a rare cutting endonuclease, the proportion
of cells modiﬁed by the nuclease could vary over time,
probably due to nuclease toxicity (34). We actually
observed a similar phenomenon, whereas treatment with
the non-toxic Rag1m molecule results in a stable rate of
1% of TM, most of the events generated by CLS4076m
at Day 2 (5% of TM) have disappeared by Day 13
(Supplementary Figure S2a). Thus, cell death resulting
from MN toxicity could impact with apparent efﬁcacy
of MN, especially when measured after day several days.
We assessed the toxicity of allMNs featured in this study,
using a cell survival assay that was previously validated
and relies on decreased green ﬂuorescent protein (GFP)
expression as a read-out for cellular toxicity (16,20,35;
Supplementary Figure S2b and S2c). Toxicity was MN
dose-dependent and typically ranged between that of
I-SceI (the most speciﬁc reported rare-cutting endonucle-
ase) and I-CreI, with the exception of two MNs (CLS3899
andCLS4633, see Table 1). Importantly, toxicity was found
not to be related to the level of activity (r=0. 15 with
P=0.52; and r=0.14 with P=0.43).
However, no correlation could be established between
toxicity and efﬁcacy. The estimated values of linear
(Pearson’s r) and non-linear (Spearman, r) correlation
coefﬁcients between TM and toxicity are 0.04 and 0.03,
respectively, with corresponding P-values of 0.81 and 0.86,
respectively. Therefore, we looked for more complex
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Figure 3. Characterization of MNs efﬁcacy on their chromosomal
cognate target. (a) A chromosomal assay for the characterization of
MN-induced TM. MN expressing vectors are transfected into 293-H
cells; the targeted locus is ampliﬁed by PCR and 10 000 molecules (on
average) are sequenced to detect indels. (b) A chromosomal test for the
detection of MN-induced HGT. MN-expressing vectors are
co-transfected into 293-H cells together with a repair matrix; cells are
grown in 96-well plates, and targeted alleles are detected by PCR.
(c) Comparison between the TM and HGT assays in 293-H cells.
Eighteen MNs were characterized in both assays (Table 1). Dotted
grey curves represent 95% conﬁdence interval for the regression line.
Linear regression ﬁts the formula y=5.46x 0.66. r, Pearson coefﬁ-
cient (linear correlation coefﬁcient); r, Spearman coefﬁcient (non-linear
correlation coefﬁcient); N, sample size; P: probability of ﬁnding a given
correlation when the underlying variables are not correlated.
(d) Comparison between the TM and HGT frequencies measured sim-
ultaneously by deep sequencing. Sixteen independent experiments were
conducted, using different MNs (Rag1m, ADCY9m, CLS3676m,
CLS3759m, CLS3894m, CLS4076m and CLS4607m), promoters
(SV40 or CMV) and vector concentrations, all described in
Supplementary Table S2. Dotted grey curves represent 95% conﬁdence
interval for the regression line. Linear regression ﬁts the formula
y=1.71x+0.20. r, r, P and N have the same meaning as on the
previous panel.
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correlations factors. Supplementary Figure S2d features
an attempt of correlation between toxicity, on the one
hand, and the ratio of the efﬁcacy of TM in 293-H cells
versus the activity in the extrachromosomal assay in
CHO-KI cell (TM/SSA ratio), on the other. Correlation
coefﬁcients are very low, with very high P-values (r=0.16
with P=0.42; and r=0.03 with P=0.86), indicating a
lack of correlation, in spite of the relatively large sample
size (n=39). Fitting of TM as a linear function of toxicity
and SSA (TM= a*SSA+b*TOX+c), lead to similar
results with a=2.38 (P=9 103), b=0.24
(P=0.55) and c=7.9385 (P=2 104). This outcome
indicates that when measuring the contribution of activity
in CHO-KI cells (SSA) and toxicity (TOX) to efﬁcacy, the
contribution of activity in CHO-KI cell is signiﬁcant
(P=9 103), consistent with the results shown in
Figure 4a for the same sample, but the contribution of
toxicity is not (P=0.55), consistent with the results of
Supplementary Figure S2d.
While toxicity has no direct correlation with the efﬁcacy
of TM, it seems that it might play an important role in the
dynamic of TM over time. There is a signiﬁcant cor-
relation between toxicity and the ratio of TM in 293-H
at Day 7 versus Day 2 (r=0.86 P=6 103; r=0.9,
P=5 103), with more toxic MNs having a bigger
drop in the efﬁcacy of TM from Day 2 to Day 7.
In conclusion, whereas toxicity can impact the apparent
efﬁcacy of MNs, it cannot account for the global
discrepancies observed between the on extrachromosomal
and chromosomal targets, and MN efﬁcacy is not solely
the consequence of its intrinsic properties (activity and
toxicity). Therefore, we decided to test the impact of ex-
trinsic factors, such as chromatin-based position effect.
MN efﬁcacy is strongly correlated with chromosomal
position effects
Chromatin-based position effects could impact on MN
efﬁcacy by modulating access of the MN, the repair
matrix and/or cellular repair factors to the target DNA.
Eukaryotic genomes are packaged in chromatin, and
nuclease sensitivity remains one of the main methods
used to monitor chromatin accessibility and/or the
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Figure 4. The efﬁcacy of MNs on their chromosomal target is poorly correlated with the activity of the nucleases in extrachromosomal assays.
Throughout the ﬁgure, r, Pearson coefﬁcient (linear correlation coefﬁcient); r, Spearman coefﬁcient (non-linear correlation coefﬁcient); N, sample
size; P, probability of ﬁnding a given correlation when the underlying variables are not correlated. (a) Comparison between the extrachromosomal
SSA assay in CHO-KI and the TM assay in HEK293 cells. Thirty-seven MNs cleaving 39 targets were tested in both assays (Table 1). Correlation
was also made with a smaller sample of 18 MNs (black circles), which are the same as the 18 MNs characterized in the HGT assay (Figure 3b), and
displayed on Figure 3c. Vertical grey lines represent the activity levels of I-SceIm (left line) and Rag1m (right line). (b) Correlation between the
extrachromosomal SSA assays in 293-H cells and the TM assay in 293-H cells. (c) Correlation between the extrachromosomal SSA assays in CHO
cells and the HGT assay in 293-H cells. (d) Correlation between the extrachromosomal SSA assays in 293-H cells and the HGT assay in 293-H cells.
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(a)
(b)
(c)
(d)
(e) (f)
Figure 5. Impact of position effect on MNs efﬁcacy. (a) The Rag1m MNs as well as Iso1Rag1m and Iso2Rag1m, two isoschizomers were tested for
activity in our extrachromosomal assay in CHO-KI cells, for toxicity, and for their ability to induce targeted insertion at the endogenous Rag1 locus.
Activity, efﬁcacy and toxicity assays were conducted as described in Figures 2 and 3. (b) Similar studies were conducted with the DMD21m MN and
Iso1DMDm and Iso2DMDm cleaving the DMD21t target. (c) The CLS3902m MN cleaves a sequence found in four copies in the human.
CLS3902m was tested for activity, toxicity and efﬁcacy of targeted mutagenesis at three of its cognate targets, CLS3902t_5, CLS3902t_7 and
CLS3902t_14. In A, B and C, each value is the average of two independent experiments but for Rag1m (n=7) and DMD21 (n=3).
(d) CHART-PCR assay for micrococcal nuclease accessibility of the Rag1t, DMD21t, CLS3902t_5, CLS3902t_7, CLS3902t_14, CLS4076t,
CAPNS1t, ADCY9t, CLS3759t and XPC4t loci. The GAPDH and PAX7 loci are used as controls for accessible and non accessible chromatin,
respectively (37). Nuclei were isolated and treated with various amounts of micrococcal nuclease, and for each locus, the amount of non digested
DNA was monitored by Q-PCR as described in materials and methods. Data are normalized to the value obtained in absence of nuclease, and each
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positioning of nucleosomes in vivo (24,25). Nuclease acces-
sibility is known to vary largely across the genome and at
least in the promoter region, to correlates with a transcrip-
tionally active state (24,36). In order to assess the possible
role of chromatin position effect on genome editing using
MN, we ﬁrst compared (i) the efﬁcacy of different MNs
(isoschizomers) at the same locus (ii) the efﬁcacy of the
same MN at different loci.
The Rag1m MN cleaves a sequence from the human
Rag1 gene (16). DMD21m cleaves a sequence from the
38th intron of the gene (Table 1). Several isoschizomers
were obtained when we engineered these proteins, and
we compared Rag1m and DMD21m with two additional
isoschizomers. At each individual locus, efﬁcacy was
found to correlate with activity in CHO-KI cells (Figs.
5a and 5b), with the most active cognate MN giving the
highest rates of HGT. However, this correlation was not
found when comparing the results achieved at the two loci.
For example, the iso2DMDm MN is signiﬁcantly less
active than the iso2RAG1m MN, but has a similar
efﬁcacy. Thus, efﬁcacy is correlated with activity in
CHO-KI cells only when assessed at the ‘same target
locus’. We also characterized CLS3902m, a MN whose
cognate target is found four times in the genome.
CLS3902m has the same activity as Rag1m, and a
slightly higher toxicity (Figure 5c). Examination of TM
at three target loci (the fourth one could not be ampliﬁed
by PCR) gave clearly different frequencies of events,
ranging from 0.39% to 1.17% at Day 2 and from 0.13
to 0.75 at Day 7 (Figure 5c), demonstrating locus
dependence.
This type of position effect is likely the consequence of
chromatin-based differences of target accessibility. We
used CHART-PCR (36,37) to test micrococcal nuclease
accessibility at 10 loci targeted by eight engineered MNs
(Figure 5d), and a nuclease resistance index (AUC) was
calculated for each locus, as indicated in ﬁgure legend and
‘Materials and Method’ section. CLS4076t and CAPNS1t,
two targets for which we observed very high rates of TM,
were indeed located in very accessible regions.
Interestingly, CAPNS1t is in a non-methylated CpG
island in the 50UTR of the CAPNS1 gene, whereas
CLS4076t is close to a CpG island, about 4 kb upstream
of the region coding for the FUT8 protein. More gener-
ally, a very strong ‘negative’ correlation was observed
between nuclease resistance and percentage of TM per
chromatid at Day 2 (Figure 5e) and at Day 7
(Figure 5f), ﬁtting with strong linear correlation between
log (TM) and accessibility index (r=0.93 with
P=7 105and r=0.87 with P=2 103, respect-
ively). Thus, target accessibility is a major determinant
of efﬁcacy of rare-cutting designer endonucleases.
DISCUSSION
We describe here the ﬁrst genome-wide study of a rare-
cutting designer endonuclease platform. We showed that a
wide range of efﬁcacies of TM and HGT (between 0.1%
and 15%) can be achieved in human cells using MNs. This
provides an effective benchmark for genome editing. In
addition, these comprehensive studies allow us to accur-
ately address several long-standing questions. In particu-
lar, since both TM and HGT depend on cellular DNA
repair mechanisms, it is tempting to hypothesize that
HGT and TM would be correlated at the genome level.
Moreover, the potential impact of chromosomal context
and epigenetics on designer endonuclease-mediated
genome editing remains largely unexplored. Our current
study is the ﬁrst of its kind that speciﬁcally addresses the
role of chromosomal context and epigenetics in genome
editing.
Our comprehensive analysis revealed a robust genome-
wide correlation between MN-induced HGT and
MN-induced TM (r=0.93; P=2 108). Thus, the efﬁ-
ciency of repair of a designer endonuclease-induced
DSB by either NHEJ or homologous recombination es-
sentially depends on extrinsic factors at the cellular level
(although one cannot exclude subtle locus-speciﬁc or
MN-speciﬁc differences). One of the direct consequences
is that the TM rate, which is relatively easy to monitor, is
predictive of the HGT rate, which monitoring requires the
construction of a repair matrix and a more sophisticated
protocol. Therefore, TM can be used as a surrogate assay
to investigate the ability of a given locus to be edited by
MN-induced HGT. We could actually infer a global rela-
tively constant HGT/TM ratio throughout the genome
close to 1.7 in 293-H cells. This ratio is likely to be
cell-type dependent, particularly since HGT is thought
to be largely dependent on the rate of cell division (38).
It would be interesting to determine whether, the average
HGT/TM ratio is similar or substantially different with
alternative platforms, such as ZFNs or TALENs in the
same cell type.
The availability our comprehensive platform of MN
allowed us to assess the potential impact of chromosomal
context and epigenetics on rare-cutting endonuclease-
mediated genome editing. In particular, it has long been
assumed that the efﬁcacy of these nucleases could be
subject to position effects. We showed here that ‘extrinsic’
factors (i.e. chromosome locus) have a strong impact that
can outweighs that of ‘intrinsic’ factors (i.e. MN activity,
expression, toxicity) on the net MN efﬁcacy. Most import-
antly, molecular analysis shows a very robust correlation
between chromatin accessibility and MN ‘efﬁcacy’, which
appears as a key predictive factor in genome engineering
Figure 5. Continued
point is the average of four measurements from two independent experiments. (e) Comparison between the micrococcal nuclease accessibility assay
and the TM assay at Day 2. The values of panel d were used to construct a curve, and a nuclease resistance index (AUC) was calculated as the AUC,
based on the same principle as activity and cell survival index calculations (Figure 2b and h). Efﬁcacy of TM at Day 2 was plotted against this
resistance index, using a semi-logarithmic scale. Here, r represents the linear correlation coefﬁcient between log(TM) and AUC. r, Pearson coefﬁcient
(linear correlation coefﬁcient); r, Spearman coefﬁcient (non-linear correlation coefﬁcient); N, sample size; P, probability of ﬁnding a given correlation
when the underlying variables are not correlated. (f) Comparison between the micrococcal nuclease accessibility assay and the TM assay at Day 7.
Here, r represents the linear correlation coefﬁcient between log(TM) and AUC.
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experiments. These results should not hide the fact that at
a given individual locus, the most active isoschizomers will
have the highest efﬁcacies, as shown on Figure 5a and b.
However, these results underscore the potential import-
ance of chromosomal context and epigenetic factors in
genome editing using designer rare-cutting endonucleases.
Our results also argue that relatively simple techniques
such as CHART-PCR, or the simple data mining of
existing databases could be used to better predict the
loci allowing for the best efﬁciencies. The promoters or
50UTR regions of housekeeping genes could be ideal
targets for applications requiring high efﬁcacies, as
illustrated by the high efﬁcacies observed with the
CAPNS1t and CLS4076t targets. Consequently, our
results set the stage for a more rational design of
genome engineering strategies using designer endonucle-
ases and contribute to a better understanding of their
properties at the genome-wide level. It is likely that
chromosomal position effects and epigenetics, particularly
target site accessibility, will have broad implications for
other genome engineering platforms such as those based
on ZFNs and TALENs.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online:
Supplementary Tables S1–S6, Supplementary Figures
S1–S2.
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